Headlines

Pfizer, BioNTech lose UK appeal to overturn Moderna's COVID vaccine patent win

Published by Global Banking & Finance Review

Posted on August 1, 2025

1 min read

· Last updated: January 22, 2026

Add as preferred source on Google
Pfizer, BioNTech lose UK appeal to overturn Moderna's COVID vaccine patent win
Global Banking & Finance Awards 2026 — Call for Entries

LONDON (Reuters) -Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal. Last

Pfizer and BioNTech's Appeal Against Moderna Patent Ruling Denied

LONDON (Reuters) -Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal.

Last year, the High Court ruled that one of Moderna's patents relating to the messenger RNA (mRNA) technology which underpinned its COVID-19 vaccine was valid and that Pfizer and BioNTech's Comirnaty vaccine had infringed it, meaning Moderna is entitled to damages in relation to sales after March 2022.

Pfizer and Moderna had appealed to try to overturn that decision, arguing Moderna's developments of mRNA technology were obvious developments of previous work, rendering the patent invalid.

(Reporting by Sam Tobin; Editing by Catarina Demony)

Key Takeaways

  • Pfizer and BioNTech lost their appeal against Moderna in the UK.
  • The appeal was regarding a COVID-19 vaccine patent infringement.
  • London's Court of Appeal upheld Moderna's patent validity.
  • Moderna is entitled to damages for sales after March 2022.
  • Pfizer argued the patent was an obvious development of prior work.

Frequently Asked Questions

What was the outcome of Pfizer and BioNTech's appeal?
Pfizer and BioNTech lost their bid to overturn a ruling regarding patent infringement at London's Court of Appeal.
What technology is at the center of the patent dispute?
The dispute revolves around a patent related to messenger RNA (mRNA) technology, which is fundamental to Moderna's COVID-19 vaccine.
What did Pfizer and Moderna argue in their appeal?
They argued that Moderna's developments of mRNA technology were obvious advancements of prior work, which should render the patent invalid.

Tags

Related Articles

More from Headlines

Explore more articles in the Headlines category